CCDC153

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, CCDC153 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CCDC153 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CCDC153 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC153 expression acts as an unfavorable survival marker.

BLCA and COAD are the cancer types where CCDC153 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
BLCADFSMedianAll0.1340.617<.00118view →
COADOSMedianAll0.1720.870<.00115view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CCDC153–BLCA (DFS)

Kaplan–Meier survival curve for CCDC153 mutant vs wild-type samples in BLCA.

Open the BLCA breakdown →

Exploration